ArticleJournal of clinical medicine2020
Feasibility and Acceptability of
Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Stepped-care models for cancer symptom management: a systematic review of efficacy and cost-effectiveness.Journal of the National Cancer Institute · 2026Pooled it
- Experience and Needs of Immunotherapy for Lung Cancer Patients: A Meta-Synthesis of Qualitative Studies.Psycho-oncology · 2025Pooled it
- A systematic review with evidence mapping of supportive care interventions for melanoma patients and caregivers.Cancer medicine · 2023Pooled it
- Operationalizing fear of cancer recurrence care: a modified Delphi study establishing a consensus-based clinical pathway for Danish cancer survivors.Acta oncologica (Stockholm, Sweden) · 2026Article
- Living well with advanced cancer: a scoping review of non-pharmacological supportive care interventions.Journal of cancer survivorship : research and practice · 2026Article
- Step-by-step: A clinical pathway for stepped care management of fear of cancer recurrence-results of a three-round online delphi consensus process with Australian health professionals and researchers.Journal of cancer survivorship : research and practice · 2026Article
- Dynamic Association Between Health Literacy and Fear of Progression Among Nasopharyngeal Cancer Survivors During the Post‑treatment Survivorship Period: A Multicenter Exploratory Longitudinal Study.Patient preference and adherence · 2026Article
- Feasibility and Acceptability of the Fear-Less Screening and Stratified-Care Model for Fear of Cancer Recurrence Among People Affected by Early-Stage Cancer.Psycho-oncology · 2025Article
- Review
- For the Long Haul: Management of Long-Term Survivors after Melanoma Systemic Therapy.Current oncology reports · 2024Review
- Article
- Article
- Article
- Fear of Cancer Recurrence in peritoneal malignancy patients following treatment: a cross-sectional study.Journal of cancer survivorship : research and practice · 2023Article
- Psychosocial Aspects of Living Long Term with Advanced Cancer and Ongoing Systemic Treatment: A Scoping Review.Cancers · 2022Article
- Study protocol for the evaluation of Fear-Less: a stepped-care program for fear of cancer recurrence in survivors with early-stage disease.Pilot and feasibility studies · 2022Article
- Article
- Article
- Fear of Progression, Anxiety, and Depression in Patients With Advanced Melanoma in the COVID-19 and Post-COVID-19 Era.Frontiers in psychiatry · 2022Article
- A Multi-step Approach to Adapting a Mind-Body Resiliency Intervention for Fear of Cancer Recurrence and Uncertainty in Survivorship (IN FOCUS).Global advances in health and medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 7 institutions in 1 country.
Funding
Abstract
Immunotherapies and targeted therapies have revolutionised treatment of metastatic melanoma and improved survival rates. However, survivors treated with novel therapies are vulnerable to high levels of fear of cancer recurrence or progression (FCR). Existing FCR interventions have rarely been trialled in people with advanced cancer. The current study aimed to evaluate the acceptability and feasibility of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.